Form 4: Twist Bioscience Legal Officer Sells Shares to Cover Tax Obligations
Insider Transaction Report
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 531 shares of common stock to satisfy tax withholding obligations related to vested restricted stock units.
Summary
- Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp (TWST), reported a sale of 531 shares of common stock.
- The transaction occurred on May 21, 2025, at a price of $29.747 per share.
- Following this transaction, Mr. Cho beneficially owns 105,318 shares of common stock.
- The sale was a "sell to cover" transaction, mandated by the company's equity incentive plans to satisfy tax withholding obligations upon the vesting of Restricted Stock Units, and was not a discretionary trade by Mr. Cho.
Sentiment
Score: 5
Explanation: The transaction is a non-discretionary "sell to cover" to satisfy tax obligations, which is a routine administrative event and does not reflect a change in the officer's investment sentiment or the company's performance.
Positives
- The transaction is a non-discretionary "sell to cover" to meet tax obligations, indicating a routine administrative event rather than a voluntary sale by the officer.
- The officer continues to hold a significant number of shares (105,318), demonstrating continued alignment with shareholder interests.
Future Outlook
No forward-looking statements or guidance are provided in this Form 4 filing.
Management Comments
- "Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person."
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction and does not provide information relevant to broader industry trends or competitors. "Sell to cover" transactions are common across all industries for executives receiving equity compensation.
Comparison to Industry Standards
- Not applicable. This document reports a standard insider transaction (sell-to-cover) which is a common practice for executives to manage tax liabilities on vested equity awards across various industries. There are no specific comparable companies, projects, or results to list.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization for SEC Filings | Granting of Power of Attorney to Dennis Cho, Judy Yan, and Kendra Fox to act as attorney-in-fact for Section 16 reporting persons, including managing EDGAR accounts and filing Forms 3, 4, and 5. | 05/08/2025 | Enhances efficiency and compliance for insider trading reporting requirements by centralizing the filing process through designated attorneys-in-fact. |
Stakeholder Impact
- Minimal direct impact on shareholders, employees, customers, suppliers, or creditors as this is a routine, non-discretionary insider transaction for tax purposes. It does not signal any change in company operations or financial health.
Key Dates
| Date | Description |
|---|---|
| 05/08/2025 | Date of execution of the Power of Attorney document. |
| 05/21/2025 | Date of the reported transaction (sale of common stock). |
| 05/23/2025 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Twist Bioscience, TWST, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Officer Transaction, Dennis Cho, Biotechnology, Synthetic Biology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.